MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.  The company was founded in 2012 and is headquartered in Brisbane, California.

Bristol-Myers

The deal was a big bet on one promising pipeline drug.

Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia

EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation

MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients

MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association's Scientific Sessions 2020

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

MyoKardia Reports Third Quarter 2020 Financial Results

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia's mission to promote understanding and treatment of the underlying drivers of serious cardiovascular diseases. 

MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 1

Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period

EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation

MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association's Annual Scientific Sessions 2020

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM and R&D successes will have made the acquisition a good bargain.

Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to MyoKardia, Inc. (NASDAQ:MYOK) changed recently.

Were Hedge Funds Right About Crowding Into MyoKardia, Inc. (MYOK)?

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...

SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - MYOK, EIDX, CBMG

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating MyoKardia, Inc. ("MyoKardia" or the "Company") (MYOK) relating to...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of MyoKardia, Inc. - MYOK

Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.

Here's Why Bristol Myers Offered MyoKardia $13.1 Billion

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded Myokardia from Outperform to Neutral and raised the price target from $127 to $225.

Myokardia Analysts See Mavacamten As Blockbuster Opportunity For Bristol-Myers Squibb

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. ("MYOK" or the "Company") (NASDAQ: MYOK) in connection with the proposed acquisition of the Company by...

SHAREHOLDER ALERT: WeissLaw LLP Investigates MyoKardia, Inc.

"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.

Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 per share in cash is fair to MyoKardia shareholders. On behalf of MyoKardia shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are a MyoKardia shareholder and woul

MyoKardia Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of MyoKardia, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MYOK

MyoKardia's major, $13.1 billon deal with fellow pharmaceutical company Bristol Myers Squibb sent MYOK stock soaring on Monday. The post M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal appeared first on InvestorPlace.

M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal

The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.

Bristol Myers Squibb Begins a $13.1 Billion Purchase of MyoKardia

Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.

Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/65214_07983442142dc8e4_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of MyoKardia, Inc. to Bristol Myers Squibb

MyoKardia Inc. (NASDAQ: MYOK) shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb Co.

MyoKardia Shareholders Are Getting a Really Sweet Payday

Bristol Myers Squibb said it reached an agreement to acquire MyoKardia for $13.1 billion, adding to its portfolio of treatments for cardiovascular diseases but sending BMY stock down early. The post Bristol Myers Squibb To Add To Heart Treatment Portfolio With $13.1 Billion Acquisition appeared first on Investor's Business Daily.

Bristol Myers Squibb To Add To Heart Treatment Portfolio With $13.1 Billion Acquisition

The heart disease specialist fetches a rather rich buyout offer from Bristol Myers Squibb.

News for MyoKardia Stock (MYOK)